Chapter 1: Executive Summary
Chapter 2: Small Interfering RNAs (siRNAs)
Introduction
Background of Small Interfering RNAs2-3Discovery of RNAi
MicroRNAs
2-3Discovery of RNAi
2-5Current Frontier of Research in RNAi
2-8siRNA Vector Systems
2-10Viral Vectors
2-13Lentivirus Vectors
2-13Lentivirus Vectors
2-14Transfection
2-16In vivo siRNA Delivery
2-17Cholesterol Conjugation for
2-17Specificity of RNAi Molecule
2-18Stabilization of RNA Dimers For Therapeutic Treatments
2-18Duration of RNAi Activity
2-20RNAi Microarrays
2-20Pathway Analysis and Libraries
2-21RNAi Libraries
2-21Genome-Wide Screens and Signaling Pathway Analysis
2-21Patents
2-22References
Chapter 3: Markets
3-1Market Drivers
3-1Cost of Drug Developments
3-1Demand for High-Throughput Target Discovery
3-2Demand for Target Validation
3-2Demand For New Therapeutics
3-3Diseases Ideal for siRNA Therapeutic
3-3Diseases Ideal for siRNA Therapeutic
3-5Viral Infectious Disease
3-7Hepatitis C
3-8HIV
3-9Hepatitis B
3-10Influenza
3-10Severe Acute Respiratory Syndrome Virus (SARS)
3-11Polio Virus
3-11Respiratory Synctial Virus
3-11CNS Disease
3-11Cardiovascular Disease
3-13Other Indications
3-14References
Chapter 4: Other RNAi Technology in Target Validation and Therapeutics
Antisense
4-1Ribozyme
4-3Aptamers
4-4Peptide Nucleic Acids
4-5Morpholino Antisense Nucleotides
4-5References
Chapter 5: Other Rival Technologies In Target Validation
5-1Gene Knockouts
5-1Mice and Rats
5-1Zebra Fish
5-3References
Chapter: 6 Related Technologies Critical To High-Throughput Target Validation
6-1Protein Profiling Technology
6-1Cell Microarrays
6-1Phenotype Profiling Technology
6-2References
Chapter 7: Profiles of Companies Developing siRNA Therapeutics
7-1Acuity Pharmaceuticals
7-1AGY Therapeutics
7-3Alnylam Pharmaceuticals, Inc.
7-6Antisense Therapeutics Limited
7-11Benitec Australia Limited
7-14CytRx Corporation
7-17Genta Incorporated
7-19Hemispherx Biopharma, Inc.
7-23International Therapeutics
7-26Intradigm Corporation
7-28ISIS Pharmaceuticals
7-36Noxxon Pharma AG
7-36Nucleonics Inc.
7-39Sirna Therapeutics, Inc.
Chapter 8: Profiles of Companies Developing siRNA-mediated Target Validation
8-1AtugenAG
8-1Cenix Bioscience GmbH
8-4Compugen Ltd.
8-7deVGen nv
8-10Galapagos Genomics nv .
8-13Immusol Inc.
8-16Ingenium Pharmaceuticals AG
8-19Lexicon Genetics
8-22Phenomix Corporation Phenomix Australia Pty Ltd.
8-26Phylonix Pharmaceuticals, Inc
8-29RNAx GmbH
8-31Zygogen LLC
Chapter 9: Profiles of Companies Specialized in siRNA and siRNA-related Reagents
9-1Allele Biotechnology and Pharmaceuticals, Inc.
9-1amaxa GmbH .
9-3Ambion, Inc. …
9-5CombiMatrix Corporation
9-9Cyclacel
9-12Cyntellect, Inc.
9-15Dharmacon, Inc.
9-17Eurogentec
9-20ExpressOn BioSystems Ltd .
9-22Gene Therapy Systems, Inc.
9-24Imgenex Corp.
9-26Invitrogen Corporation
9-31 Mirus Bio Corporation
9-33Ocimum Biosolutions LLC…
9-37Oligoengine, Inc.
9-39Polyplus-transfection SAS
9-40Proligo
9-42Qiagen N.V
Chapter 10: Trends
10-1Strengths
Weaknesses
0-1Opportunities
0-3Threats
